Gosset Ownership
Public
Therapeutic Areas
Stage
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
PainReform General Information
The lead candidate, PRF‑110, demonstrated a solid safety profile with no serious adverse events in early Phase III trials for bunionectomy patients. Plasma concentrations were well below FDA safety thresholds. However, the company encountered a temporary setback due to a data gap in the final phase of its Phase III trial and has initiated further R&D to address this before resuming clinical work.
Contact Information
Drug Pipeline
PRF-110
Phase 3Key Partnerships
PainReform Funding
No funding data available
To view PainReform's complete valuation and funding history, request access »
PainReform Financial Metrics
Market Cap
$163.1K
Enterprise Value
$-3259923